Table 1. Pre-operative characteristics of clinical stage I cases.
| Characteristics | RS (n=62) | PS (n=63) | P value |
|---|---|---|---|
| Age (years) | 66±10 | 73±8 | <0.001 |
| Sex (%) | 0.015 | ||
| Male | 29 (46.8) | 43 (68.3) | |
| Female | 33 (53.2) | 20 (31.7) | |
| Size of tumor (mm) | <0.001 | ||
| Range | 6–25 | 3–54 | |
| Mean | 15±5 | 21±9 | |
| FDG-PET (SUV) | 1.2±1.5 | 5.6±6.5 | <0.001 |
| C/T ratio (%) | 52±37 | 73±37 | 0.001 |
| CEA (ng/mL) | 3.0±2.1 | 6.2±8.3 | 0.004 |
| %VC | 113±18 | 106±19 | 0.045 |
| FEV1.0 (mL) | 1,945±893 | 1,823±748 | 0.410 |
| Clinical stage (%) | 0.001 | ||
| IA | 60 (96.8) | 48 (76.2) | |
| IB | 2 (3.2) | 15 (23.8) |
RS, radical segmentectomy; PS, palliative segmentectomy; C/T ratio, consolidation/tumor (C/T) ratio obtained with thin-sliced computed tomography; FDG-PET, 2-deoxy-2 [18F] fluorodeoxyglucose positron emission tomography; SUV, standardized uptake value; CEA, carcinoembryonic antigen; %VC, % vital capacity; FEV1.0, forced expiratory volume in 1 s.